|1.||Balboni, Gianfranco: 5 articles (08/2010 - 12/2002)|
|2.||Salvadori, Severo: 4 articles (08/2010 - 12/2002)|
|3.||Lazarus, Lawrence H: 4 articles (08/2010 - 12/2002)|
|4.||Negri, Lucia: 3 articles (01/2009 - 12/2002)|
|5.||Marczak, Ewa D: 2 articles (08/2010 - 01/2009)|
|6.||Giannini, Elisa: 2 articles (07/2004 - 12/2002)|
|7.||Bryant, Sharon D: 2 articles (07/2004 - 12/2002)|
|8.||Jinsmaa, Yunden: 2 articles (07/2004 - 12/2002)|
|9.||Guerrini, Remo: 2 articles (07/2004 - 12/2002)|
|10.||Schiller, Peter W: 1 article (02/2012)|
08/15/2010 - "Whereas, H-Dmt-Tic-Asp *-Bid is a potent and selective delta agonist (MVD, IC(50)=0.12nM); H-Dft-Tic-Asp *-Bid and H-Tyr-Tic-Asp *-Bid are potent and selective delta antagonists (pA(2)=8.95 and 8.85, respectively). "
12/05/2002 - "Conversion of delta-opioid receptor antagonists containing the 2',6'-dimethyl-L-tyrosine (Dmt)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) pharmacophore into potent delta-agonists required a third heteroaromatic nucleus, such as 1H-benzimidazole-2-yl (Bid) and a linker of specified length both located C-terminally to Tic in the general formula H-Dmt-Tic-NH-CH(R)-R'. "
01/17/2000 - "A series of Dmt-Tic analogues with substitution on the Tic aromatic ring has been synthesized and evaluated for opioid receptor affinity and activation. "
01/01/1997 - "Discovery of high affinity and ultraselective delta opioid dipeptide antagonists composed of 2',6'-dimethyl-L-tyrosyl (Dmt) and 1,2,3,4-tetrahydroisoquinoline-3-carboxylic (Tic) served as the basis for the conformationally restricted diketopiperazine cyclo(Dmt-Tic) and related open chain analogues. "
07/29/2004 - "These compounds were designed to test the following hypothesis: the physicochemical properties of third-residue substitutions C-terminal to Tic in the Dmt-Tic pharmacophore modify delta-opioid receptor selectivity and delta-opioid receptor antagonism through enhanced interactions with the mu-opioid receptor. "
07/01/2007 - "The main findings are that (1) similar to DADLE (10 microM), H-Dmt-Tic-NH-CH (CH(2)--COOH)-Bid (1-10 microM), a more specific and potent DOR agonist significantly attenuated anoxic K(+) derangement in cortical slice; (2) [D-Ala(2), N-Me-Phe(4), glycinol(5)]-enkephalin (DAGO; 10 microM), a MOR agonist, did not produce any appreciable change in anoxic disruption of K(+) homeostasis; (3) absence of Ca(2+) greatly attenuated anoxic K(+) derangement; (4) inhibition of Ca(2+)-activated K(+) (BK) channels with paxilline (10 microM) reduced anoxic K(+) derangement; (5) DADLE (10 microM) could not further reduce anoxic K(+) derangement in the Ca(2+)-free perfused slices or in the presence of paxilline; and (6) glybenclamide (20 microM), a K(ATP) channel blocker, decreased anoxia-induced K(+) derangement, but DADLE (10 microM) could further attenuate anoxic K(+) derangement in the glybenclamide-perfused slices. "
|1.||delta Opioid Receptors (delta Opioid Receptor)
|3.||2- tyrosyl- 1,2,3,4- tetrahydroisoquinoline- 3- carboxylic acid
|5.||Large-Conductance Calcium-Activated Potassium Channels (Maxi-K Channels)
|6.||Ala(2)-MePhe(4)-Gly(5)- Enkephalin (DAGO)
|7.||Opioid Peptides (Opioid Peptide)
|8.||mu Opioid Receptors (mu Opioid Receptor)
|9.||Leucine-2-Alanine Enkephalin (Enkephalin, Leucine 2 Alanine)
|10.||Opioid Receptors (Opioid Receptor)
|1.||Drug Therapy (Chemotherapy)